Welcome to our dedicated page for Abivax news (Ticker: ABVX), a resource for investors and traders seeking the latest updates and insights on Abivax stock.
Abivax SA reports developments as a clinical-stage biotechnology company developing therapeutics that modulate immune response in chronic inflammatory diseases. Its news centers on obefazimod (ABX464), the company’s lead therapeutic candidate, including clinical and preclinical data in inflammatory bowel disease, Phase 3 ABTECT work in moderately to severely active ulcerative colitis, and related safety, efficacy, biomarker, and patient-reported outcome analyses.
Recurring updates also cover financial results, annual and regulatory reporting in France and the United States, American Depositary Share offerings, royalty certificate obligations, public-company governance, annual meeting materials, and trading references for its Euronext Paris and Nasdaq-listed securities.
Abivax (Euronext Paris/Nasdaq: ABVX) expanded its Commercial Leadership Team with four senior appointments across marketing, patient services, sales/commercial operations, and market access/pricing. The company stated these roles are intended to support the potential U.S. commercialization of its lead candidate obefazimod, ahead of a planned NDA submission to the FDA in Q4 2026.
James Berger becomes Global Head of Marketing, leading commercial strategy and brand development for obefazimod. Ivan Nuñez-Pacheco is appointed Global Head of Patient Services, overseeing the global patient services model. Heather Dean assumes the role of Global Head of Sales, Accounts & Commercial Operations, while Jeff Haas becomes Global Head of Market Access & Pricing, responsible for market access and pricing strategies.
Abivax (NASDAQ:ABVX) closed its underwritten public offering of 7,360,000 ADSs in the US, including full exercise of the underwriters’ option. The Offering generated gross proceeds of about $920.0 million and estimated net proceeds of about $874.1 million.
According to Abivax, combining these funds with existing cash is expected to finance operations into Q4 2029. The company’s ordinary shares trade on Euronext Paris and its ADSs on Nasdaq, both under the symbol ABVX.
Abivax (Nasdaq:Euronext: ABVX) announced that underwriters fully exercised their option to buy 960,000 additional ADSs, bringing the total Offering to 7,360,000 ADSs.
This increases gross proceeds to about $920.0M (€807.4M) and estimated net proceeds to about $874.1M (€767.1M), mainly to fund obefazimod commercialization and inflammatory bowel disease R&D.
Abivax (Nasdaq: ABVX) priced an upsized underwritten public offering of 6,400,000 ADSs at $125.00 per ADS, raising expected gross proceeds of about $800M (€702M), with a 15% underwriters’ option. The deal is priced at a 2.39% premium and is expected to extend the cash runway into Q2 2029, funding potential commercialization of obefazimod and continued clinical development.
Abivax (Euronext Paris: ABVX) announced that trading of its ordinary shares on Euronext Paris will resume on July 1, 2026 at 3:30 p.m. CEST.
Trading was halted at the Company’s request from 9:00 a.m. CEST in connection with allocation confirmation and pricing of its US ADS public offering.
Abivax (Nasdaq: ABVX) priced an oversubscribed, upsized underwritten public offering of 6,400,000 ADSs at $125.00 per ADS, raising expected gross proceeds of about $800M (€702M), excluding any underwriters’ option exercise.
Net proceeds and existing cash are expected to fund operations, including potential obefazimod commercialization and clinical development, into Q2 2029. Dilution is estimated at 8.0–9.2%, depending on full exercise of the 960,000 ADS underwriters’ option.
Abivax (ABVX), a clinical-stage biotechnology company, requested a temporary halt of trading in its ordinary shares on Euronext Paris from 9:00 a.m. CEST on July 1, 2026. The halt supports confirming allocations and announcing pricing for a previously announced ADS public offering in the United States. Trading is expected to resume around 3:30 p.m. CEST the same day.
Abivax (Nasdaq: ABVX) launched an underwritten public offering of approximately $600 million of American Depositary Shares in the United States, with an underwriters’ option for up to 15% additional ADSs.
Proceeds are intended for potential commercialization of obefazimod in the US, clinical R&D in ulcerative colitis and Crohn’s disease, and general corporate purposes. The offering will cause dilution and is subject to market conditions.
Abivax (Nasdaq:ABVX) reported topline Phase 3 ABTECT Maintenance Part 2 data for obefazimod in refractory ulcerative colitis. Among induction non-responders treated with 50 mg through Week 44, 37.2% achieved clinical remission and 34.5% endoscopic remission.
In patients relapsing during Maintenance Part 1, dose escalation or re-treatment with 50 mg recaptured clinical remission in about 45%. Across the integrated Phase 2/3 UC program (1,704 patient‑years), exposure‑adjusted malignancy and non‑melanoma skin cancer rates remained within published UC background ranges. Abivax plans a UC NDA submission in Q4 2026.
Abivax (Nasdaq:ABVX) reported topline Phase 3 ABTECT maintenance results for oral obefazimod in moderately to severely active ulcerative colitis.
At Week 44, clinical remission was 50.8% (25 mg) and 51.3% (50 mg) versus 10.4% placebo; all key secondary endpoints were met and safety was favorable. An NDA filing for UC is planned for Q4 2026, with Phase 2b Crohn’s induction topline data expected mid-2027.